Improved survival in resected biliary malignancies

Attila Nakeeb, Khoi Q. Tran, Michael J. Black, Beth A. Erickson, Paul S. Ritch, Edward J. Quebbeman, Stuart D. Wilson, Michael J. Demeure, William S. Rilling, Kulwinder S. Dua, Henry A. Pitt

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Background. For many years the prognosis for patients with biliary malignancies has been poor. However, recent advances in radiology and laparoscopy have improved staging, and active biliary stent management may improve outcome in these patients. In the past the goal with surgery was to excise all gross tumor. Now, the surgical goal is to achieve negative microscopic margins even if a major hepatic resection is required. Similarly, chemotherapy or radiation was frequently given in isolation, but chemoradiation has become the standard. Therefore, the aim of this analysis was to determine whether survival has improved with better staging, active stent management, more aggressive surgery, and chemoradiation. Methods. From 1990 through 2001, 140 patients with biliary malignancies were treated at the Medical College of Wisconsin. One hundred eleven malignancies were cholangiocarcinomas (intrahepatic, 22%; perihilar, 65%; and distal, 13%), and 29 were gallbladder (GB) cancers. Eighty-six of the 140 patients (61%) underwent exploration (intrahepatic, 58%; perihilar, 57%; distal, 67%, and GB, 72%). Forty-four of these 86 patients (51%) underwent resection (intrahepatic, 64%; perihilar, 41%; distal, 70%; and GB, 52%). Chemoradiation with confocal radiation, 5-fluorouracil, and gemcitabine was used more frequently in the patients resected since 1998. Results. Thirty-day operative mortality was 4%. In the resected patients (n = 44) the 5-year actuarial survival was 31% and the median survival was 27.8 months. Patients resected between 1998 and 2001 (n = 25) had a median survival longer than 44 months with a 3-year actuarial survival of 70% as compared to patients resected between 1990 and 1997 (n = 19), who had a median survival of 13 months and a 3-year actuarial survival of 21% (P <.01). Conclusions. These data suggest that (1) approximately one third of patients with biliary malignancies have resectable disease and (2) surgery in carefully selected patients with adjuvant chemoradiation has improved survival in resected patients. We suspect that a combination of improved staging, active biliary stenting, safe but extensive surgery to obtain negative margins, and newer techniques for chemoradiation have resulted in improved outcomes for patients with biliary malignancies.

Original languageEnglish (US)
Pages (from-to)555-564
Number of pages10
JournalSurgery
Volume132
Issue number4
DOIs
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Survival
Neoplasms
gemcitabine
Gallbladder
Stents
Radiation
Gallbladder Neoplasms
Cholangiocarcinoma
Radiology
Fluorouracil
Laparoscopy
Drug Therapy
Mortality
Liver

ASJC Scopus subject areas

  • Surgery

Cite this

Nakeeb, A., Tran, K. Q., Black, M. J., Erickson, B. A., Ritch, P. S., Quebbeman, E. J., ... Pitt, H. A. (2002). Improved survival in resected biliary malignancies. Surgery, 132(4), 555-564. https://doi.org/10.1067/msy.2002.127555

Improved survival in resected biliary malignancies. / Nakeeb, Attila; Tran, Khoi Q.; Black, Michael J.; Erickson, Beth A.; Ritch, Paul S.; Quebbeman, Edward J.; Wilson, Stuart D.; Demeure, Michael J.; Rilling, William S.; Dua, Kulwinder S.; Pitt, Henry A.

In: Surgery, Vol. 132, No. 4, 01.10.2002, p. 555-564.

Research output: Contribution to journalArticle

Nakeeb, A, Tran, KQ, Black, MJ, Erickson, BA, Ritch, PS, Quebbeman, EJ, Wilson, SD, Demeure, MJ, Rilling, WS, Dua, KS & Pitt, HA 2002, 'Improved survival in resected biliary malignancies', Surgery, vol. 132, no. 4, pp. 555-564. https://doi.org/10.1067/msy.2002.127555
Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ et al. Improved survival in resected biliary malignancies. Surgery. 2002 Oct 1;132(4):555-564. https://doi.org/10.1067/msy.2002.127555
Nakeeb, Attila ; Tran, Khoi Q. ; Black, Michael J. ; Erickson, Beth A. ; Ritch, Paul S. ; Quebbeman, Edward J. ; Wilson, Stuart D. ; Demeure, Michael J. ; Rilling, William S. ; Dua, Kulwinder S. ; Pitt, Henry A. / Improved survival in resected biliary malignancies. In: Surgery. 2002 ; Vol. 132, No. 4. pp. 555-564.
@article{d5cfcd46437e43c99cabfd15dcdaeecd,
title = "Improved survival in resected biliary malignancies",
abstract = "Background. For many years the prognosis for patients with biliary malignancies has been poor. However, recent advances in radiology and laparoscopy have improved staging, and active biliary stent management may improve outcome in these patients. In the past the goal with surgery was to excise all gross tumor. Now, the surgical goal is to achieve negative microscopic margins even if a major hepatic resection is required. Similarly, chemotherapy or radiation was frequently given in isolation, but chemoradiation has become the standard. Therefore, the aim of this analysis was to determine whether survival has improved with better staging, active stent management, more aggressive surgery, and chemoradiation. Methods. From 1990 through 2001, 140 patients with biliary malignancies were treated at the Medical College of Wisconsin. One hundred eleven malignancies were cholangiocarcinomas (intrahepatic, 22{\%}; perihilar, 65{\%}; and distal, 13{\%}), and 29 were gallbladder (GB) cancers. Eighty-six of the 140 patients (61{\%}) underwent exploration (intrahepatic, 58{\%}; perihilar, 57{\%}; distal, 67{\%}, and GB, 72{\%}). Forty-four of these 86 patients (51{\%}) underwent resection (intrahepatic, 64{\%}; perihilar, 41{\%}; distal, 70{\%}; and GB, 52{\%}). Chemoradiation with confocal radiation, 5-fluorouracil, and gemcitabine was used more frequently in the patients resected since 1998. Results. Thirty-day operative mortality was 4{\%}. In the resected patients (n = 44) the 5-year actuarial survival was 31{\%} and the median survival was 27.8 months. Patients resected between 1998 and 2001 (n = 25) had a median survival longer than 44 months with a 3-year actuarial survival of 70{\%} as compared to patients resected between 1990 and 1997 (n = 19), who had a median survival of 13 months and a 3-year actuarial survival of 21{\%} (P <.01). Conclusions. These data suggest that (1) approximately one third of patients with biliary malignancies have resectable disease and (2) surgery in carefully selected patients with adjuvant chemoradiation has improved survival in resected patients. We suspect that a combination of improved staging, active biliary stenting, safe but extensive surgery to obtain negative margins, and newer techniques for chemoradiation have resulted in improved outcomes for patients with biliary malignancies.",
author = "Attila Nakeeb and Tran, {Khoi Q.} and Black, {Michael J.} and Erickson, {Beth A.} and Ritch, {Paul S.} and Quebbeman, {Edward J.} and Wilson, {Stuart D.} and Demeure, {Michael J.} and Rilling, {William S.} and Dua, {Kulwinder S.} and Pitt, {Henry A.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1067/msy.2002.127555",
language = "English (US)",
volume = "132",
pages = "555--564",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Improved survival in resected biliary malignancies

AU - Nakeeb, Attila

AU - Tran, Khoi Q.

AU - Black, Michael J.

AU - Erickson, Beth A.

AU - Ritch, Paul S.

AU - Quebbeman, Edward J.

AU - Wilson, Stuart D.

AU - Demeure, Michael J.

AU - Rilling, William S.

AU - Dua, Kulwinder S.

AU - Pitt, Henry A.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Background. For many years the prognosis for patients with biliary malignancies has been poor. However, recent advances in radiology and laparoscopy have improved staging, and active biliary stent management may improve outcome in these patients. In the past the goal with surgery was to excise all gross tumor. Now, the surgical goal is to achieve negative microscopic margins even if a major hepatic resection is required. Similarly, chemotherapy or radiation was frequently given in isolation, but chemoradiation has become the standard. Therefore, the aim of this analysis was to determine whether survival has improved with better staging, active stent management, more aggressive surgery, and chemoradiation. Methods. From 1990 through 2001, 140 patients with biliary malignancies were treated at the Medical College of Wisconsin. One hundred eleven malignancies were cholangiocarcinomas (intrahepatic, 22%; perihilar, 65%; and distal, 13%), and 29 were gallbladder (GB) cancers. Eighty-six of the 140 patients (61%) underwent exploration (intrahepatic, 58%; perihilar, 57%; distal, 67%, and GB, 72%). Forty-four of these 86 patients (51%) underwent resection (intrahepatic, 64%; perihilar, 41%; distal, 70%; and GB, 52%). Chemoradiation with confocal radiation, 5-fluorouracil, and gemcitabine was used more frequently in the patients resected since 1998. Results. Thirty-day operative mortality was 4%. In the resected patients (n = 44) the 5-year actuarial survival was 31% and the median survival was 27.8 months. Patients resected between 1998 and 2001 (n = 25) had a median survival longer than 44 months with a 3-year actuarial survival of 70% as compared to patients resected between 1990 and 1997 (n = 19), who had a median survival of 13 months and a 3-year actuarial survival of 21% (P <.01). Conclusions. These data suggest that (1) approximately one third of patients with biliary malignancies have resectable disease and (2) surgery in carefully selected patients with adjuvant chemoradiation has improved survival in resected patients. We suspect that a combination of improved staging, active biliary stenting, safe but extensive surgery to obtain negative margins, and newer techniques for chemoradiation have resulted in improved outcomes for patients with biliary malignancies.

AB - Background. For many years the prognosis for patients with biliary malignancies has been poor. However, recent advances in radiology and laparoscopy have improved staging, and active biliary stent management may improve outcome in these patients. In the past the goal with surgery was to excise all gross tumor. Now, the surgical goal is to achieve negative microscopic margins even if a major hepatic resection is required. Similarly, chemotherapy or radiation was frequently given in isolation, but chemoradiation has become the standard. Therefore, the aim of this analysis was to determine whether survival has improved with better staging, active stent management, more aggressive surgery, and chemoradiation. Methods. From 1990 through 2001, 140 patients with biliary malignancies were treated at the Medical College of Wisconsin. One hundred eleven malignancies were cholangiocarcinomas (intrahepatic, 22%; perihilar, 65%; and distal, 13%), and 29 were gallbladder (GB) cancers. Eighty-six of the 140 patients (61%) underwent exploration (intrahepatic, 58%; perihilar, 57%; distal, 67%, and GB, 72%). Forty-four of these 86 patients (51%) underwent resection (intrahepatic, 64%; perihilar, 41%; distal, 70%; and GB, 52%). Chemoradiation with confocal radiation, 5-fluorouracil, and gemcitabine was used more frequently in the patients resected since 1998. Results. Thirty-day operative mortality was 4%. In the resected patients (n = 44) the 5-year actuarial survival was 31% and the median survival was 27.8 months. Patients resected between 1998 and 2001 (n = 25) had a median survival longer than 44 months with a 3-year actuarial survival of 70% as compared to patients resected between 1990 and 1997 (n = 19), who had a median survival of 13 months and a 3-year actuarial survival of 21% (P <.01). Conclusions. These data suggest that (1) approximately one third of patients with biliary malignancies have resectable disease and (2) surgery in carefully selected patients with adjuvant chemoradiation has improved survival in resected patients. We suspect that a combination of improved staging, active biliary stenting, safe but extensive surgery to obtain negative margins, and newer techniques for chemoradiation have resulted in improved outcomes for patients with biliary malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0036776052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036776052&partnerID=8YFLogxK

U2 - 10.1067/msy.2002.127555

DO - 10.1067/msy.2002.127555

M3 - Article

C2 - 12407338

AN - SCOPUS:0036776052

VL - 132

SP - 555

EP - 564

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 4

ER -